Conavi MedicalCNVIF 4 EBITDA Margin % is -3,275.79% as of Mar. 2026. GuruFocus rates CNVIF with a GF Score™ of 4/100. The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Conavi Medical ranks worse than 95.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Conavi Medical's EBITDA for the
three
months ended in Mar. 2026 was $-3.11 Mil. Conavi Medical's Revenue for the
three
months ended in Mar. 2026 was $0.10 Mil. Therefore, Conavi Medical's EBITDA margin for the quarter that ended in Mar. 2026 was -3,275.79%.
Conavi Medical (OTCPK:CNVIF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Conavi Medical EBITDA Margin % Related Terms
Conavi Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Conavi Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNVIF vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Conavi Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Conavi Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Conavi Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Conavi Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conavi Medical (CNVIF) has a EBITDA Margin % of -3,275.79% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Conavi Medical and its competitors. According to the industry distribution chart, Conavi Medical ranks #777 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 95.2%.
Is Conavi Medical's EBITDA Margin % too high?
Conavi Medical's current EBITDA Margin % is -3,275.79%. Based on the distribution chart, Conavi Medical ranks #777 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Conavi Medical has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Conavi Medical's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Conavi Medical ranks #777 out of 816 companies for EBITDA Margin %. This places Conavi Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Conavi Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Conavi Medical's current EBITDA Margin % is -3,275.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conavi Medical stock overvalued right now?
Conavi Medical (CNVIF) has a current EBITDA Margin % of -3,275.79%. The current EBITDA Margin % is -3,275.79%. Conavi Medical's overall GF Score™ is 4/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Conavi Medical (CNVIF), the current EBITDA Margin % is -3,275.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Conavi Medical Corp is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its Novasight Hybrid System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries.
4GF Score
Get the complete analysis for CNVIF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNVIF has been successfully added to your 
